Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Novel Biomarker Tests Increase Accuracy of Breast and Lung Cancer Diagnoses

January 23rd 2023

Andrew McKenzie, PhD, discusses biomarkers to test for in breast and lung cancers, the value of multicancer early detection, and how biomarker testing can better direct targeted treatment across solid tumors.

Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer

January 23rd 2023

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Neoadjuvant Treatment of HER2+ Early Breast Cancer

January 20th 2023

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

January 20th 2023

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.

Dr. Dhakal on the Evolution of Pertuzumab Regimens in HER2+ Breast Cancer

January 18th 2023

Ajay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.

Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer

January 18th 2023

Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.

Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer Dormancy

January 18th 2023

Jose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.

Clinical Implications of SERENA-2 Trial Data

January 18th 2023

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

Novel Agents in the Adjuvant Setting: PARP Inhibitors

January 18th 2023

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer

January 18th 2023

Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.

Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer

January 16th 2023

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification

January 16th 2023

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

Dr. O’Regan on the SOFT Trial in Premenopausal Women With HR+ Breast Cancer

January 12th 2023

Ruth M. O’Regan, MD, discusses the significance of the Breast Cancer Index as a prognostic tool, as well as the investigation of the phase 3 SOFT trial for patients with early-stage, hormone receptor-positive breast cancer.

Dr. Mayer on the PACE Trial in HR+/HER2– Breast Cancer

January 12th 2023

Erica L. Mayer, MD, MPH, discusses findings from the phase 2 PACE trial in patients with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer.

Dr. Jimenez on the Management of Radiation Toxicities in Breast Cancer

January 12th 2023

Rachel Jimenez, MD, discusses the management of toxicities associated with radiotherapy for patients with breast cancer.

Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast Cancer

January 12th 2023

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.

FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer

January 11th 2023

The FDA has granted a fast track designation to best-in-class threonine tyrosine kinase inhibitor CFI-402257 for the treatment of adult patients with estrogen receptor (ER)–positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.